Sonova Holding AG (SONVY)
60.77
-0.18
(-0.30%)
USD |
OTCM |
Jun 25, 16:00
Sonova Enterprise Value: 19.25B for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 19.25B |
| June 24, 2024 | 19.30B |
| June 21, 2024 | 19.19B |
| June 20, 2024 | 19.43B |
| June 18, 2024 | 19.41B |
| June 17, 2024 | 19.41B |
| June 14, 2024 | 19.68B |
| June 13, 2024 | 20.02B |
| June 12, 2024 | 20.10B |
| June 11, 2024 | 20.27B |
| June 10, 2024 | 20.18B |
| June 07, 2024 | 20.28B |
| June 06, 2024 | 20.53B |
| June 05, 2024 | 20.43B |
| June 04, 2024 | 20.36B |
| June 03, 2024 | 19.91B |
| May 31, 2024 | 20.10B |
| May 30, 2024 | 19.91B |
| May 29, 2024 | 19.94B |
| May 28, 2024 | 20.05B |
| May 24, 2024 | 20.29B |
| May 23, 2024 | 20.38B |
| May 22, 2024 | 20.05B |
| May 21, 2024 | 19.54B |
| May 20, 2024 | 20.04B |
| Date | Value |
|---|---|
| May 17, 2024 | 20.28B |
| May 16, 2024 | 20.65B |
| May 15, 2024 | 20.78B |
| May 14, 2024 | 19.99B |
| May 13, 2024 | 18.68B |
| May 10, 2024 | 18.93B |
| May 09, 2024 | 18.78B |
| May 08, 2024 | 18.63B |
| May 07, 2024 | 18.65B |
| May 06, 2024 | 18.41B |
| May 03, 2024 | 18.52B |
| May 02, 2024 | 18.16B |
| May 01, 2024 | 17.84B |
| April 30, 2024 | 17.65B |
| April 29, 2024 | 18.06B |
| April 26, 2024 | 17.93B |
| April 25, 2024 | 17.61B |
| April 24, 2024 | 17.80B |
| April 23, 2024 | 17.78B |
| April 22, 2024 | 17.75B |
| April 19, 2024 | 17.31B |
| April 18, 2024 | 17.30B |
| April 17, 2024 | 17.41B |
| April 16, 2024 | 17.66B |
| April 15, 2024 | 17.78B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
9.192B
Minimum
Mar 23 2020
26.26B
Maximum
Apr 01 2022
17.38B
Average
16.30B
Median
Enterprise Value Benchmarks
| AC Immune SA | 280.41M |
| CRISPR Therapeutics AG | 2.642B |
| Addex Therapeutics Ltd | 6.723M |
| NLS Pharmaceutics Ltd | 8.04M |
| Molecular Partners AG | 50.90M |
Enterprise Value Related Metrics
| Earnings Yield | 3.77% |
| Operating Earnings Yield | 4.20% |
| Normalized Earnings Yield | 3.768 |